ARCTURUS THERAPEUTICS HOLDIN (ARCT)
US03969T1097 - Common Stock
ARCT gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 568 industry peers in the Biotechnology industry. ARCT scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ARCT is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
ARCT had negative earnings in the past year.
ARCT had a negative operating cash flow in the past year.
ARCT had negative earnings in 4 of the past 5 years.
ARCT had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
ARCT has a better Return On Assets (-16.90%) than 80.00% of its industry peers.
ARCT has a Return On Equity of -23.92%. This is amongst the best in the industry. ARCT outperforms 82.48% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -16.9% | ||
| ROE | -23.92% | ||
| ROIC | N/A |
ROA(3y)-18.91%
ROA(5y)-20.7%
ROE(3y)-32.17%
ROE(5y)-43.09%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ARCT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
ARCT does not have a ROIC to compare to the WACC, probably because it is not profitable.
ARCT has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, ARCT has more shares outstanding
ARCT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
ARCT has an Altman-Z score of 1.29. This is a bad value and indicates that ARCT is not financially healthy and even has some risk of bankruptcy.
With a decent Altman-Z score value of 1.29, ARCT is doing good in the industry, outperforming 67.79% of the companies in the same industry.
ARCT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.29 |
ROIC/WACCN/A
WACC11.96%
2.3 Liquidity
ARCT has a Current Ratio of 4.76. This indicates that ARCT is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of ARCT (4.76) is comparable to the rest of the industry.
A Quick Ratio of 4.76 indicates that ARCT has no problem at all paying its short term obligations.
ARCT has a Quick ratio (4.76) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.76 | ||
| Quick Ratio | 4.76 |
3. Growth
3.1 Past
The earnings per share for ARCT have decreased strongly by -159.84% in the last year.
The Revenue for ARCT has decreased by -45.85% in the past year. This is quite bad
The Revenue has been growing by 60.22% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-159.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%57.38%
Revenue 1Y (TTM)-45.85%
Revenue growth 3Y159.91%
Revenue growth 5Y60.22%
Sales Q2Q%-7.68%
3.2 Future
The Earnings Per Share is expected to grow by 58.76% on average over the next years. This is a very strong growth
Based on estimates for the next years, ARCT will show a very strong growth in Revenue. The Revenue will grow by 34.31% on average per year.
EPS Next Y-140%
EPS Next 2Y-39.51%
EPS Next 3Y40.06%
EPS Next 5Y58.76%
Revenue Next Year0.98%
Revenue Next 2Y2.83%
Revenue Next 3Y25.12%
Revenue Next 5Y34.31%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
ARCT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ARCT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
ARCT's earnings are expected to grow with 40.06% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-39.51%
EPS Next 3Y40.06%
5. Dividend
5.1 Amount
No dividends for ARCT!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ARCTURUS THERAPEUTICS HOLDIN
NASDAQ:ARCT (12/20/2024, 8:00:00 PM)
After market: 15.48 0 (0%)15.48
+0.64 (+4.31%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners93.2%
Inst Owner Change-0.31%
Ins Owners1.37%
Ins Owner Change-0.33%
Market Cap419.35M
Analysts85.88
Price Target70.72 (356.85%)
Short Float %17.62%
Short Ratio11.24
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)69.89%
Min EPS beat(2)60.74%
Max EPS beat(2)79.04%
EPS beat(4)4
Avg EPS beat(4)56.42%
Min EPS beat(4)17.53%
Max EPS beat(4)79.04%
EPS beat(8)7
Avg EPS beat(8)347.67%
EPS beat(12)10
Avg EPS beat(12)237.61%
EPS beat(16)11
Avg EPS beat(16)170.2%
Revenue beat(2)2
Avg Revenue beat(2)68.47%
Min Revenue beat(2)11.64%
Max Revenue beat(2)125.3%
Revenue beat(4)3
Avg Revenue beat(4)59.34%
Min Revenue beat(4)-11.98%
Max Revenue beat(4)125.3%
Revenue beat(8)6
Avg Revenue beat(8)69.98%
Revenue beat(12)8
Avg Revenue beat(12)161.24%
Revenue beat(16)8
Avg Revenue beat(16)112.68%
PT rev (1m)0.32%
PT rev (3m)-7.09%
EPS NQ rev (1m)12.92%
EPS NQ rev (3m)-308.45%
EPS NY rev (1m)23.96%
EPS NY rev (3m)19.18%
Revenue NQ rev (1m)-0.07%
Revenue NQ rev (3m)-39.13%
Revenue NY rev (1m)-5.03%
Revenue NY rev (3m)-5.41%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 2.61 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.6 | ||
| P/tB | 1.6 | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.22
EYN/A
EPS(NY)-2.02
Fwd EYN/A
FCF(TTM)-2.27
FCFYN/A
OCF(TTM)-2.22
OCFYN/A
SpS5.92
BVpS9.67
TBVpS9.67
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -16.9% | ||
| ROE | -23.92% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-18.91%
ROA(5y)-20.7%
ROE(3y)-32.17%
ROE(5y)-43.09%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.43
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 42.89% | ||
| Cap/Sales | 0.95% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.76 | ||
| Quick Ratio | 4.76 | ||
| Altman-Z | 1.29 |
F-Score3
WACC11.96%
ROIC/WACCN/A
Cap/Depr(3y)296.63%
Cap/Depr(5y)241.64%
Cap/Sales(3y)11%
Cap/Sales(5y)11.05%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-159.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%57.38%
EPS Next Y-140%
EPS Next 2Y-39.51%
EPS Next 3Y40.06%
EPS Next 5Y58.76%
Revenue 1Y (TTM)-45.85%
Revenue growth 3Y159.91%
Revenue growth 5Y60.22%
Sales Q2Q%-7.68%
Revenue Next Year0.98%
Revenue Next 2Y2.83%
Revenue Next 3Y25.12%
Revenue Next 5Y34.31%
EBIT growth 1Y-230.97%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-18.34%
EBIT Next 3Y-31.37%
EBIT Next 5YN/A
FCF growth 1Y64.95%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y64.81%
OCF growth 3YN/A
OCF growth 5YN/A